Introduction
The high prevalence of constipation in patients with cancer has been described in the preceding article. 1 This condition can produce some of the most distressing symptoms of cancer and cancer treatment, thus appreciably affecting quality of life, daily living, and self-esteem. 2 Untreated constipation may contribute to increased abdominal pain and distention, urinary retention, nausea, vomiting, and anorexia, as well as the development of hemorrhoids, anal fissures, perianal abscesses, and intestinal obstruction. [2] [3] [4] Anal fissures and perianal abscesses can lead to systemic infections in neutropenic patients. 2 This review focuses on the pharmacologic management of constipation as it pertains to cancer patients.
Management of Constipation
A discussion on the evaluation and assessment of patients with constipation is included in the previous article, and general measures such as mobilization and hydration are presented. 1 The effective management of constipation in cancer patients often times requires the appropriate use of laxatives. This article focuses on the appropriate use of laxatives and other pharmacologic agents. In addition, it is important to review all the medications being taken by a patient in order to consider discontinuing nonessential constipating drugs such as phenothiazines, iron sulfate, and constipating antacids. Table 1 lists several drugs other than opioids that can contribute to the onset of constipation.
Mechanism of Action
Laxative drugs can be classified by their mechanism of action. This classification includes bulk-forming, emollient, osmotic/saline, stimulant, and lubricant laxatives. Other pharmacologic agents, including prokinetic agents and opioid antagonists, are also used in the armamentarium against the constipating effects of cancer therapy (Tables 2 and 3) .
Bulk-Forming Laxatives
Bulk-forming laxatives most closely approximate the physiologic mechanisms involved in promoting evacuation. They are available as natural or semisynthetic hydrophilic polysaccharides, cellulose derivatives, or polyacrylic resins. They include methylcellulose, psyllium, and polycarbophil. These agents either dissolve or swell in the intestinal fluid, forming a viscous liquid that facilitates the passage of intestinal contents, stimulates peristalsis, and reduces transit time. 7 They are not absorbed systemically and do not seem to disrupt nutrient absorption, although administration with other medications such as warfarin, digoxin, and potassium-sparing diuretics may decrease the effects of these medications. 8 Bulk-forming agents begin to exert their effects in 2 to 4 days. Since they take effect in approximately 72 hours, it is not ideal for the initial management of symptomatic constipation.
Bulk-forming agents are typically recommended as initial therapy for most forms of mild constipation. 7 Increasing dietary fiber intake, whether through diet or with bulk agents, often can reverse mild or transient cases of constipation. 9 These agents may be beneficial in cancer patients who have a good performance status or who are not concurrently receiving constipating medications such as narcotics, antiemetics, or vinca alkaloids. They may also be useful in patients with colostomies. 7 However, these agents are not ideal for most indications involving constipation in cancer patients. The powder and granule products need to be mixed with fluids and taken in a full 8-ounce dosage. The daily dosage is then titrated based on response. 10 Due to the hydration requirement needed to appropriately administer these products (the usual goal of fluid intake being 30 mL/kg per day), many patients with advanced cancer, particularly elderly patients, are not suitable candidates for bulkforming laxatives. Administering these laxatives to this population may predispose them to fecal impaction and bowel obstruction. These products are used with caution in patients with esophageal strictures, ulcers, stenosis, or intestinal adhesions and are contraindicated in patients who have obstructive symptoms or fecal impaction. In addition, patients who have slow GI transit (eg, secondary to opioid use) or other defecation disorders are less likely to respond to bulk-forming agents than patients without these conditions.
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The two most common adverse effects of increasing fiber intake (either through diet or bulk-forming products) are abdominal pain and bloating. 11 However, these symptoms are expected during the first few weeks of therapy and decrease in severity over time. 10 They can be avoided by gradually increasing the dosage. 10 Bloating is less common with cellulose derivatives because they do no undergo bacterial fermentation. 10 Bulk-forming agents are considered an appropriate first-line therapy for those patients who meet adequate fluid-intake requirements; they should be avoided in those who are unable to maintain adequate fluid intake and should not be used as single-agent therapy for those patients receiving opioid analgesics.
Emollient Laxatives
Emollient laxatives increase the wetting efficiency of intestinal fluid and facilitate the mixing of aqueous and fatty substances that soften feces. Docusate is known as a stool softener and comes in various forms: docusate calcium, docusate sodium, and docusate potassium. The onset of action is usually seen after 1 to 2 days but may take as long as 3 to 5 days. Like the bulk-forming laxatives, emollient laxatives require increased fluid intake to facilitate stool softening. In prescribing these agents, practitioners should avoid concurrent administration of poorly absorbed drugs such as mineral oil. Administering these drugs together may increase the absorption of the mineral oil, thereby increasing the risk of toxicity. 7 Emollient laxatives serve little value by themselves in the treatment of long-term constipation. They may be beneficial when given concurrently with bulk-forming agents so as to reduce straining. 12 Traditionally, these agents are indicated in cases of acute perianal disease in order to soften and avoid painful defecation or to avoid straining. Stool softeners are beneficial when the addition of dietary fiber or bulk-forming agents and fluids is insufficient to produce a soft stool. 3 They can also be Improves gastric tone and peristalsis; increases resting esophageal sphincter tone; relaxes pyloric sphincter; augments duodenal peristalsis, leading to increased gastric emptying and decreased transit time through duodenum, jejunum, and ileum used as first-line therapy in the prevention of iatrogenic or drug-related constipation. 2 They do not stimulate peristalsis and evacuation; however, they can be used in combination with stimulant laxatives to provide a softer stool that is easier to evacuate.
Mechanism of Action Comments

Osmotic/Salines Laxatives
Osmotic laxatives work by attracting and retaining fluid into the bowel to form softer stool. Many medications, including lactulose, sorbitol, polyethylene glycol (PEG) compounds, and saline laxatives (eg, magnesium hydroxide), fall under the classification of osmotic laxatives. Lactulose and sorbitol are nonabsorbable sugars that are hydrolyzed into organic acids, drawing fluid osmotically into the intestinal lumen to stimulate propulsion and motility. 11 The onset of effect is usually seen 24 to 72 hours once the drug has reached the colon. However, adverse effects such as abdominal pain or distention may arise shortly after ingestion. These adverse effects subside after a few days. Larger doses of lactulose tend to result in bloating and colic. 13 Both lactulose and sorbitol have been shown to be equally effective in relieving idiopathic constipation in elderly patients. 11 Their sweet tastes and the production of flatulence may cause problems with compliance in cancer patients. Mixing lactulose with fruit juice, water, or milk may increase palatability, but if the patient is already nauseated, these medications may exacerbate complaints. Sorbitol may be less nauseating than lactulose, 11 and some guidelines have suggested that lactulose should be used only for the treatment of encephalopathy and not for constipation. 2 Polyethylene glycol-electrolyte solution is an osmotic laxative that traditionally has been used for GI lavage solutions prior to procedures. It is designed to rapidly cleanse the GI tract without disturbing the patient's water and electrolyte balance. Long-term use of this colon lavage solution (200 to 500 mL per day) has been studied and suggested as an option for patient's bowel regimens. 9, 14, 15 Both GoLYTELY and NuLYTELY solutions appear to be equally efficacious for colonoscopy preparation, but the latter does not contain sodium sulfate. A 500-mL dose of GoLYTELY would provide more than half of the US recommended daily sodium allowance. 15 Since NuLYTELY does not contain sodium sulfate, this may be an advantage for use in patients who have sodium restrictions. 9 PEG 3350 (MiraLax) contains no electrolytes and may be used for cancer patients who fail to respond to bulk-forming agents and saline laxatives. 10 It may be preferred over lactulose or sorbitol since these agents are associated with increased gas production, cramping, and abdominal distention, 10 and PEG 3350 is tasteless and has low toxicity. The recommended starting dose of PEG 3350 without electrolytes is 17 g per day. These agents typically produce a bowel movement within 24 to 48 hours.
Glycerin, a trihydroxy alcohol, is considered a hyperosmotic laxative. It is administered rectally as a suppository or an enema. It helps to promote water retention to stimulate peristalsis. Unlike other osmotic laxatives, the onset of action is fairly rapid; a bowel movement usually occurs within 30 minutes of administration. Suppository dosage forms may cause bleeding, rectal discomfort, and a burning sensation. 11 Although rectally administered drugs offer a viable route of administration for cancer patients, particularly those with advanced cancer, some specific precautions are required. The rectal route is generally avoided in patients who are neutropenic because of the increased risk of bleeding/tearing and thus creating a source of ingress for blood-borne pathogens. 2 Saline osmotic laxatives include agents such as sodium phosphate (Fleets), magnesium citrate (Citroma), and magnesium hydroxide (Milk of Magnesia). These products mediate water retention osmotically, and they also stimulate peristalsis. The small intestine, acting as a semipermeable membrane to ions (magnesium, sulfate, phosphate, citrate), retains these osmotic ions in the gut. These ions with high osmotic activity draw fluid into the gut, causing an increase in intraluminal pressure. 7 This increased pressure exerts a mechanical stimulus, increasing intestinal motility. In addition, magnesium compounds can mediate water retention osmotically to stimulate peristalsis.
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Saline laxatives can produce undesirably strong purgative actions. 13 Dehydration may occur with repeated use of saline laxatives, so they should not be prescribed in patients who cannot tolerate fluid loss. 7 Also, due to their ability to cause hypomagnesemia and their high sodium content, saline laxatives should also be used with caution in cancer patients with comorbid conditions such as cardiac failure, renal insufficiency, or electrolyte disturbances. A typical oral dose of phosphate salts contains 96.5 mEq of sodium; therefore, they should be administered with caution to patients needing sodium restriction. When given via the rectal dosage form, up to 10% more sodium is absorbed. 9 Up to 20% of the magnesium ions may be absorbed from the magnesium salts administered for constipation. If a patient has impaired renal function or is elderly, toxic concentrations of magnesium can accumulate. Liquid preparations of saline laxatives may be more palatable to cancer patients if they are chilled prior to administration. 7 Citrate of magnesia is available as a carbonated liquid and may be preferred by some patients.
Saline laxatives play a limited role in the long-term management of constipation in cancer patients due to the potential for adverse effects in this population. They are beneficial in situations where acute evacuation of the bowel is desired.
11 They may also be temporarily useful in cases where symptomatic constipation is still occurring despite increased doses of stimulant laxatives and stool softeners. Saline laxatives, as well as all other osmotic laxatives, should be avoided when there is suspicion of obstruction or impaction.
The daily use of osmotic agents, excluding the saline laxatives, is indicated either as second-line or third-line agents. They may be added as second-line agents after further softening of stool and stimulation of peristalsis is needed despite using bulk-forming agents and stool softeners, or they may be added as third-line agents if stimulant laxatives, softeners, and bulk agents are insufficient to maintain normal stool elimination. 3 
Stimulant Laxatives
Stimulant laxatives include diphenylmethanes (bisacodyl) and the anthraquinones (senna and cascara). These laxatives have a more potent laxation effect than bulk-forming and osmotic laxatives and seem to be more effective than enemas. 11, 16 13 In general, stimulant laxatives are recommended for short-term treatment of constipation that is refractory to other laxatives. However, they have a more central role in the treatment of constipation in cancer patients.
Bisacodyl, a diphenylmethane stimulant, is available as a tablet or a suppository. It may be beneficial in cases of refractory constipation and in the management of cancer patients with colostomies who have managed their colostomies with routine irrigation but now find it difficult to perform this procedure. 12 Chronic use of this stimulant may lead to complications such as metabolic acidosis or alkalosis, hypocalcemia, and malabsorption. The use of bisacodyl has become more common due to withdrawal of phenolphthalein in the United States. (Phenolphthalein, another diphenylmethane derivative, was taken off the market in 1999 due to its suggested carcinogenic risk.)
Castor oil (ricinoleic acid) is also used as a stimulant laxative. However, it is rarely used for the management of constipation, and instead is used for GI tract evacuation. Abdominal cramping limits the long-term use of castor oil. 9 Furthermore, its unpleasant taste makes this option less desirable for cancer patients.
Anthraquinones are useful in opioid-induced constipation since they stimulate the myenteric plexus to induce peristalsis and reduce net absorption of water and electrolytes in the colon. The available preparations of anthraquinones are crude and contain a mixture of chemicals. 9 They are activated by bacterial metabolism in the colon. Adverse effects associated with these medications include allergic reactions, electrolyte depletion, and melanosis coli. Patients should be informed that they might experience a discoloration (red-brown, yellow-brown, or black) of their urine while taking senna. Some concerns have arisen with long-term use of anthraquinones, including a possible predisposition to colon cancer and the development of colonic inertia or a "cathartic colon." 9 Lastly, stimulant laxatives should be avoided when there is suspicion of obstruction or impaction. 12 Stimulant laxatives may be required when spontaneous defecation does not occur. 17 Stimulant laxatives,particularly senna, are often used for patients who are taking opioid narcotics, and they should also be considered for patients receiving other known constipating drugs such as vinca alkaloids. Since senna is a mild preparation with a well-controlled transit time, it is a preferred agent. 12 Agra et al 18 conducted a trial comparing the efficacy of senna (stimulant laxative) with lactulose (osmotic laxative) in 91 patients with terminal cancer who were taking either codeine or morphine. There was no difference between both agents in terms of defecation-free intervals or in days with defecation. The adverse effects produced by these laxatives were similar, leading to the conclusion that senna should be considered the laxative of choice in this setting since it is less expensive. Stimulant laxatives such as senna can be used in combination with a stool softener (eg, docusate). In fact, whenever a patient has opioid analgesics prescribed for the first time, a regular bowel regimen should be initiated, which includes a stimulant and stool softener. 17 The dosage of senna should be increased until the desired effect is achieved, up to 8 tablets a day if necessary. The doses may need to be increased if the doses of opioids are increased. Unfortunately, the quantity of tablets needed for a desired effect may rise, particularly in opioid-induced constipation, to a point that is undesirable to the patient. In this case, use of additional laxatives such as sorbitol or PEG 3350 is warranted.
Lubricant Laxatives
Lubricant laxatives alter the physical characteristics of feces by emulsifying themselves into the fecal mass. They coat the rectum as well as provide lubrication for the passage of feces. 9 Mineral oil can be used as a lubricant laxative when given either orally or as an enema. It may be useful for a patient who complains of excess straining to evacuate. Long-term use can cause malabsorption of fatsoluble vitamins. Also, foreign body reactions in the intestinal mucosa and lymph nodes may occur and aspiration of mineral oil is possible, leading to lipoid pneumonia. 9 For these reasons, mineral oil administered orally is not routinely recommended for long-term use. As mentioned earlier, the toxicity of mineral oil may be enhanced when given concurrently with docusate.
Rectal Laxatives
Rectal laxatives should not be a regular component of most cancer patients' constipation regimens. 13 However, rectal laxatives, along with digital stimulation, are necessary for treating fecal impaction, as well as treating constipation associated with spinal cord compression or neurogenic bowel dysfunction, in which case long-term use may be required. Rectal laxatives include bisacodyl (stimulant), sodium phosphate (saline), glycerin (osmotic), and mineral oil (lubricant). They are available as either suppositories or enemas, depending on the product. When evacuation of soft stools is needed, then the rectal suppository of choice is bisacodyl (stimulant). However, when a hard stool needs to be softened, then glycerin suppositories should be considered. 13 On occasion, an enema may be required for acute situations. Of note, the use of both rectal suppositories and enemas are usually contraindicated in neutropenic and thrombocytopenic patients.
Prokinetic Agents
For patients who are refractory to typical first-and secondline bowel regimens (stimulant, emollient, and osmotic laxatives) or for those who do not tolerate the side effects of such medications, prokinetic agents may be useful. 3 Metoclopramide, a gastroprokinetic agent, may be effective for delayed gastric emptying when used prior to meals and at bedtime. 12 The onset of action is with 30 to 60 minutes after an oral dose and within 1 to 3 minutes when given intravenously. The typical dose for gastroparesis is 5 to 10 mg given 30 minutes before meals and a bedtime. Adverse effects include restlessness, drowsiness, and the potential for extrapyramidal symptoms. Extrapyramidal symptoms occur more often at higher doses (1 to 2 mg/kg), at which point diphenhydramine may be coadministered to reduce this risk.
Opioid Antagonists
Opioids reduce GI propulsion, which result in slower movement of intestinal contents. This in turn allows for a more efficient absorption of water and electrolytes. They also inhibit intestinal fluid secretion, thus leading to constipation.
4 Naloxone (Narcan) is a competitive antagonist of opioid receptors. It reverses both centrally and peripherally mediated opioid effects. 19 When naloxone is administered orally, it has a bioavailability of less than 3% due to extensive (first-pass) hepatic metabolism. 4 Because of minimal absorption into the systemic circulation, oral naloxone's action is related to antagonism of opioid receptors in the GI tract, thereby reversing certain cases of idiopathic constipation. 6 The naloxone dose required to produce a laxative effect without reversing pain control may be proportional to the oral morphine doses causing constipation. 6 Many small studies have investigated the role of naloxone in reversing opioidinduced constipation. 4 It has been noted that oral naloxone's therapeutic index is narrow and that the response to opioid antagonists is proportional to the degree of opioid tolerance and not opioid levels.
The recommended starting dose of naloxone for treating opioid-induced constipation is 0.8 mg twice daily, with a maximum of 5 mg per day. It can be titrated up to 12 mg per day; however, careful observation of toxicity and decreased pain control is required. 4 Particular caution is needed for patients who are physically dependent on opioids. Naloxone may induce opioid withdrawal symptoms (tachycardia, ventricular arrhythmias, anxiety, diaphoresis, nausea, dyspnea). Doses of at least 10% of the concurrent opioid have been found to effectively reverse constipation without reversing analgesia. However, these doses may not be effective in physically dependent patients, where doses up to 20% of the total daily opioid dosage may be necessary. 4 The use of naloxone for opioid-induced constipation is still considered investigational, and the unavailability of an oral dosage formulation for naloxone in the United States limits its current use. Other opioid antagonists -naltrexone and nalmefene -are currently being investigated for this indication.
Investigational Agents
Methylnaltrexone is a quaternary ammonium opioid receptor antagonist, which limits it from crossing the blood-brain barrier. It was developed to block the peripheral GI effects of opioids while not affecting analgesia and other central effects. Methylnaltrexone is currently unavailable commercially. Several studies of both intravenous and oral dosage forms have been shown to prevent opioid effects on gastric emptying, nausea, and transit time while not affecting its analgesic action in noncancer patients (chronic methadone users). 4 Thomas et al 20 evaluated the activity of methylnaltrexone in cancer patients with advanced disease with opioid-induced constipation. Thirty patients were randomized to 4 doses (1 mg, 5 mg, 12.5 mg, or 20 mg), which were given subcutaneously every other day for 3 doses. This was followed by an openlabel phase, where patients could continue at 5 mg, followed by titration to laxation effect. Preliminary results showed a dose-related response, with most of the laxative effect occurring approximately 4 hours following dosing and an up to 70% response at the 12.5 mg dose. Adverse effects included abdominal cramping and flatulence, which were transient. 20 Another investigational agent, ADL 8-2698, is a peripherally selective µ-opioid antagonist that has potential to increase GI motility without antagonizing analgesia. 4 
Conclusions
A variety of laxatives can be used in the prevention and treatment of constipation in cancer patients. The need to treat constipation is usually a result of the failure to prevent this condition. Even though constipation may be considered preventable, it continues to occur commonly among cancer patients and is responsible for many hospital admissions. 2 Unfortunately, there are few evidencebased guidelines and published comparative studies to help guide a clinician as to the appropriate choice of laxative or dosage. Because of this, laxatives are often inappropriately prescribed, with treatment of constipation usually occurring after a significant problem arises.
2 Furthermore, maintaining an appropriate bowel regimen may be more challenging since many of the laxatives discussed can be easily acquired over-the-counter, without the advice of health professionals (Table 4) . McNicol et al 19 studied the management of opioid-induced constipation and other side effects. They determined that the type, strength, and consistency of evidence for available inter-ventions to manage opioid side effects vary from strong to weak; well-designed trials are required to establish effective management techniques to successfully address these side effects. More studies are needed to identify the most beneficial bowel regimens for prophylaxis and treatment of constipation in cancer patients. In turn, this evidencebased literature could assist in the development of better treatment guidelines that would improve the supportive care of cancer patients.
